Tg Therapeutics (TGTX) Current Assets (2010 - 2026)

Tg Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• On a quarterly basis, Current Assets rose 68.65% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 68.65% increase from a year earlier, with the FY2025 full-year figure at $630.8 million, up 11.37% from the prior year.
• Current Assets grew to $1.1 billion in Q1 2026 per TGTX's latest filing, from $630.8 million in the prior quarter.
• Across five years, Current Assets topped out at $1.1 billion in Q1 2026 and bottomed at $168.3 million in Q4 2022.
• The 5-year median for Current Assets is $360.6 million (2024), against an average of $431.9 million.
• Across the five-year window, Current Assets tumbled 55.49% in 2022 and jumped 95.14% in 2024, its largest moves.
• Year by year, Current Assets stood at $168.3 million in 2022, then surged by 88.94% to $317.9 million in 2023, then surged by 78.13% to $566.4 million in 2024, then gained by 11.37% to $630.8 million in 2025, then surged by 72.33% to $1.1 billion in 2026.
• Per Business Quant, the three latest TGTX Current Assets figures stand at $1.1 billion (Q1 2026), $630.8 million (Q4 2025), and $599.8 million (Q3 2025).